JP Morgan: STANCHART (02888) mixed fourth quarter performance, target price of 265 Hong Kong dollars, remains the top preferred stock.
Morgan Stanley expects that the group's updated guidance will lead to an upward revision of the 2026 pre-provision profit forecast by a single digit, and predicts that the group's ROTE will gradually increase, reaching around 14.5% in 2028.
JPMorgan released a research report stating that Standard Chartered (02888) fourth quarter revenue in 2025 roughly meets expectations, with net interest income exceeding expectations, but non-interest income falling short of expectations due to a temporary decline in global market business revenue. Pre-tax profit is 6% below market expectations, as costs are 4% higher than expected. Dividends are 40% higher than market expectations, while the $1.5 billion buyback plan is in line with expectations. The bank says Standard Chartered remains their preferred stock, maintaining a "buy" rating with a target price of 265 Hong Kong dollars.
Guidance for 2026 has become the focus of the market, with the group expecting a return on tangible equity (ROTE) above 12%, higher than the market's expected 11.7% and slightly higher than 2025's 11.9%. At the same time, the group anticipates revenue growth for the year to be at the lower end of the 5% to 7% expected range, indicating a 2% increase over market expectations. JP Morgan expects that the group's updated guidance will lead to a single-digit increase in pre-provision profit forecasts for 2026 and believes that the group's ROTE will gradually increase to around 14.5% by 2028.
Related Articles

HK Stock Market Move | SINOMAB BIO-B(03681) rose over 5% in the morning and is expected to launch a Phase II clinical trial for SM17 AD as early as the second quarter.
HK Stock Market Move | ADD NEW ENERGY (02623) rose nearly 15% again. The company acquired shares of an Australian gold mining company, entering the gold mining sector.

A-shares midday review: all three major indexes rose by over 1%, with the rise of price-related themes such as non-ferrous metals and chemicals exploding across the board.
HK Stock Market Move | SINOMAB BIO-B(03681) rose over 5% in the morning and is expected to launch a Phase II clinical trial for SM17 AD as early as the second quarter.

HK Stock Market Move | ADD NEW ENERGY (02623) rose nearly 15% again. The company acquired shares of an Australian gold mining company, entering the gold mining sector.
A-shares midday review: all three major indexes rose by over 1%, with the rise of price-related themes such as non-ferrous metals and chemicals exploding across the board.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


